IMPACT RCC REAL-WORLD STUDY: ECONOMIC IMPACT OF EARLY PROGRESSION AMONG PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH TYROSINE KINASE INHIBITORS IN FIRST-LINE SETTING

被引：0
|
作者：
Bhanegaonkar, A. [1 ]
Pandya, S. [2 ]
Kim, R. [3 ]
Zheng, Y. [1 ]
Dieyi, C. [2 ]
Krulewicz, S. [4 ]
Kasturi, V [1 ]
Liu, F. X. [1 ]
Hutson, T. E. [5 ]
机构：
[1] EMD Serono Inc, Rockland, MA USA
[2] STATinMED Res, Plano, TX USA
[3] Pfizer Inc, New York, NY USA
[4] Pfizer Inc, Collegeville, PA USA
[5] Texas Oncol Sammons Canc Ctr, Dallas, TX USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN114
引用
收藏
页码：S42 / S43
页数：2
相关论文
共 50 条
  • [1] Clinical impact of early progression among patients (Pts) with metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors (TKIs) in first-line (1L) setting: IMPACT RCC real-world study.
    Hutson, Thomas E.
    Liu, Frank Xiaoqing
    Pandya, Shivani
    Dieyi, Christopher
    Kim, Ruth
    Krulewicz, Stan
    Kasturi, Vijay
    Bhanegaonkar, Abhijeet
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] Effects of early vs delayed progression on clinical and economic outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first-line therapy: results from the IMPACT RCC claims data analysis
    Hutson, Thomas E.
    Liu, Frank X.
    Dieyi, Christopher
    Kim, Ruth
    Krulewicz, Stan
    Kasturi, Vijay
    Bhanegaonkar, Abhijeet
    Care, J. Manag
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (09): : 1171 - 1181
  • [3] Prediction of early progression of metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitor
    Teishima, Jun
    Murata, Daiki
    Inoue, Shogo
    Hayashi, Tetsutaro
    Mita, Koji
    Hasegawa, Yasuhisa
    Kato, Masao
    Kajiwara, Mitsuru
    Shigeta, Masanobu
    Maruyama, Satoshi
    Moriyama, Hiroyuki
    Fujiwara, Seiji
    Matsubara, Akio
    [J]. CURRENT UROLOGY, 2021, 15 (04) : 187 - 192
  • [4] The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort
    Janisch, Florian
    Hillemacher, Tobias
    Fuehner, Constantin
    D'Andrea, David
    Meyer, Christian P.
    Klotzbucher, Thomas
    Kienapfel, Christina
    Vetterlein, Malte W.
    Kimura, Shoji
    Abufaraj, Mohammad
    Dahlem, Roland
    Shariat, Shahrokh F.
    Fisch, Margit
    Rink, Michael
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (09) : 739.e9 - 739.e15
  • [5] Real-world outcomes in patients with metastatic renal cell carcinoma treated with first-line nivolumab plus ipilimumab
    Doshi, Gurjyot K.
    Robert, Nicholas J.
    Chen, Liwei
    Chan, Philip K.
    Del Tejo, Viviana
    Stwalley, Brian
    Huo, Stephen
    Geynisman, Daniel M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28)
  • [6] Prognostic outcome in patients treated with tyrosine kinase inhibitors as first-line molecular-targeted therapy for metastatic renal cell carcinoma: Experience in real-world clinical practice in Japan
    Miyazaki, Akira
    Miyake, Hideaki
    Harada, Ken-ichi
    Inoue, Taka-Aki
    Fujisawa, Masato
    [J]. MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (03) : 601 - 606
  • [7] Combination of immunotherapy and tyrosine kinase inhibitor in first-line metastatic renal cell carcinoma: A real-world Indian experience.
    Rauthan, Amit
    Patil, Poonam
    Murthy, Nitin Yashas
    Somashekhar, S. P.
    Zaveri, Shabber
    Aswath, Rajashri
    Prathyush, V
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Effect of ABO blood type on the outcomes of patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors
    Omae, Kenji
    Fukuma, Shingo
    Ikenoue, Tatsuyoshi
    Kondo, Tsunenori
    Takagi, Toshio
    Ishihara, Hiroki
    Tanabe, Kazunari
    Fukuhara, Shunichi
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (09) : 540.e7 - 540.e12
  • [9] Effect of ABO blood type on the outcomes of metastatic renal cell carcinoma patients treated with first-line tyrosine kinase inhibitors
    Omae, Kenji
    Fukuma, Shingo
    Ikenoue, Tatsuyoshi
    Kondo, Tsunenori
    Takagi, Toshio
    Ishihara, Hiroki
    Tanabe, Kazunari
    Fukuhara, Shunichi
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2018, 25 : 391 - 391
  • [10] Impact of low and high body mass index on predicting therapeutic efficacy and prognosis in patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors
    Takemoto, Kenshiro
    Sekino, Yohei
    Kitano, Hiroyuki
    Ikeda, Kenichiro
    Goto, Keisuke
    Hieda, Keisuke
    Hayashi, Tetsutaro
    Hasegawa, Yasuhisa
    Kato, Masao
    Kadonishi, Yuichi
    Kajiwara, Mitsuru
    Teishima, Jun
    Mita, Koji
    Maruyama, Satoshi
    Shigeta, Masanobu
    Hinata, Nobuyuki
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (03) : 319 - 327
12345